TIROFIBAN HYDROCHLORIDE
Tirofiban hydrochloride
How TIROFIBAN HYDROCHLORIDE Works
This drug works by blocking fibrinogen from binding to the GP IIb/IIIa receptor, which is the primary receptor on the surface of platelets responsible for clumping. By interfering with this binding process, the medication inhibits platelet aggregation in a way that depends on the dose and concentration. The effect is reversible, meaning platelet function returns to normal once the infusion is stopped.
Details
- Status
- Prescription
- First Approved
- 2021-04-08
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
TIROFIBAN HYDROCHLORIDE Approval History
What TIROFIBAN HYDROCHLORIDE Treats
1 indicationsTIROFIBAN HYDROCHLORIDE is approved for 1 conditions since its original approval in 2021. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Acute Coronary Syndrome
TIROFIBAN HYDROCHLORIDE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to TIROFIBAN HYDROCHLORIDE
3 of 8FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05604638 INSTANT | SecondAHGuangxiMU | Ph 3 | recruiting | Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke |
| NCT06587347 TREND-2 | TREND-2 | Ph 2, Ph 3 | not yet recruiting | Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke |
| NCT04818944 iTREMT | 202010341 | Ph 1, Ph 2 | withdrawn | Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
TIROFIBAN HYDROCHLORIDE FDA Label Details
Indications & Usage
TIROFIBAN HYDROCHLORIDE is indicated for the treatment of Acute Coronary Syndrome.
Looking for the branded version?
AGGRASTAT
Full clinical data, patents, trials, and competitive landscape for tirofiban hydrochloride.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.